Skip To Content

News & Events: News & Events

Posts

  • February 26 2025

    SINTX Technologies, Inc. announced the closing of its private placement in the amount of $5,000,000.  EGS acted as counsel to the placement agent.

  • February 25 2025

    Moleculin Biotech, Inc. announced the closing of its registered direct offering in the amount of $3,500,000.  EGS acted as counsel to the placement agent.

  • February 24 2025

    Client Alert Update: CTA Compliance is Back On, For Now

    As discussed in a previous Client Alert, on December 3, 2024, a federal judge in Texas instituted a nationwide preliminary injunction of the Corporate Transparency Act (“CTA”). This was followed by a separate federal court national injunction against the CTA, the effects of which were to put the obligation of companies to report their beneficial ownership information (“BOI”) to the U.S. Financial Crimes Enforcement Network (“FinCEN”) on hold.

    Click here to read the alert.

  • February 21 2025

    Intelligent Bio Solutions Inc. announced the closing of its underwritten public offering in the amount of $3,000,000.  EGS acted as counsel to the underwriter.

  • February 19 2025

    Allurion Technologies, Inc. announced the closing of its registered direct offering in the amount of $6,100,000.  EGS acted as counsel to the placement agent.

  • February 14 2025

    WiSA Technologies, Inc. announced the closing of its registered direct offering in the amount of $5,400,000.  EGS acted as counsel to the placement agent.

  • February 12 2025

    Ilya Ross, a member of the Firm, was invited by NBI (National Business Institute) to present at their Marijuana Business Law In New York online seminar on March 18, 2025.  Mr. Ross will present on two key topics: Banking and Financing for the Marijuana Industry and Legal Best Practices for Marijuana Product Packaging and Labeling.  Click here for more information.

  • February 11 2025

    RenovoRx, Inc. announced the closing of its firm commitment, underwritten public offering of common stock in the amount of $12,100,000. EGS acted as counsel to RenovoRx.

“It’s with genuine appreciation to all of our clients that we are in a position to achieve and maintain our leadership position in so many areas.”